NasdaqGS - Delayed Quote USD

Crinetics Pharmaceuticals, Inc. (CRNX)

42.12 -0.17 (-0.40%)
At close: April 26 at 4:00 PM EDT
42.12 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,013.00
4,013.00
4,737.00
1,078.00
--
Operating Expense
226,621.00
226,621.00
172,619.00
108,780.00
74,953.00
Operating Income
-222,608.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
Net Non Operating Interest Income Expense
13,436.00
13,436.00
4,317.00
157.00
991.00
Other Income Expense
-5,357.00
-5,357.00
-353.00
-96.00
150.00
Pretax Income
-214,529.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Net Income Common Stockholders
-214,529.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Diluted NI Available to Com Stockholders
-214,529.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Basic EPS
-3.69
-3.69
-3.15
-2.80
-2.42
Diluted EPS
-3.69
-3.69
-3.15
-2.80
-2.42
Basic Average Shares
58,071.00
58,071.00
51,982.00
38,436.00
30,448.00
Diluted Average Shares
58,071.00
58,071.00
51,982.00
38,436.00
30,448.00
Total Operating Income as Reported
-222,608.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
Total Expenses
226,621.00
226,621.00
172,619.00
108,780.00
74,953.00
Net Income from Continuing & Discontinued Operation
-214,529.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Normalized Income
-214,529.00
-214,529.00
-164,518.00
-107,641.00
-73,812.00
Interest Income
13,436.00
13,436.00
4,317.00
157.00
991.00
Net Interest Income
13,436.00
13,436.00
4,317.00
157.00
991.00
EBIT
-222,608.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
EBITDA
-221,510.00
-221,510.00
-166,899.00
-106,780.00
-74,005.00
Reconciled Depreciation
1,098.00
1,098.00
983.00
922.00
948.00
Net Income from Continuing Operation Net Minority Interest
-214,529.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Total Unusual Items Excluding Goodwill
--
--
600.00
--
--
Total Unusual Items
--
--
600.00
--
--
Normalized EBITDA
-221,510.00
-221,510.00
-167,499.00
-106,780.00
-74,005.00
12/31/2020 - 7/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRUS Merus N.V.
45.04
+0.24%
 
SNDX Syndax Pharmaceuticals, Inc.
21.06
+2.38%
 
IDYA IDEAYA Biosciences, Inc.
39.94
+3.42%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
GPCR Structure Therapeutics Inc.
38.94
-0.10%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
 
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%